Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer (Q57664843)
Language:
Current Data About Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer
(P31) (Q13442814)

(P50) (Q46627283)
(P1932) Christof Hofele
(P1545) 7

(Q50861917)
(P1932) Daniel Mertens
(P1545) 2

(Q42324767)
(P1932) Rajiv Kumar
(P1545) 9

(Q39509247)
(P1932) Gunnar Steineck
(P1545) 10

(Q63213683)
(P1545) 8
(P1932) Kari Hemminki

(Q66385451)
(P1545) 11
(P1932) Hartmut Döhner

(Q2076661)
(P1545) 13
(P1932) Peter Lichter

(Q47158807)
(P1545) 12
(P1932) Stephan Stilgenbauer

(P304) 1831-1835

(P407) (Q1860)

(P433) 7

(P478) 118

(P577) Saturday, April 1, 2006

(P921) (Q3421914)

(Q18348812)

(Q61659151)
(P887)

(Q29496)
(P887)

(Q268713)
(P887)

(Q504775)
(P887)

(Q1088156)
(P887)

(Q181257)
(P887)

(P1433) (Q332492)

(P1476) "Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer" (language: en)

(P2093) Stephan Wolf
(P1545) 1

Armin Pscherer
(P1545) 3

Petra Schroeter
(P1545) 4

Dirk Winkler
(P1545) 5

Hermann-Josef Gröne
(P1545) 6

other details